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Epithelial ovarian cancer is one of the commonest gynaecological
malignancies and is a leading cause of cancer death in Westernized
countries. There is an absence of symptoms in its early stages and
therefore, many patients present with advanced disease. Responses
to first line platinum-containing chemotherapy regimens are high
at 60–80% (Ozols et al, 1991; Alberts et al, 1992) however most
patients ultimately relapse and 5-year survival rates are in the
order of 20–30% (Ozols et al, 1992; Lorigan et al, 1996).
Treatment of patients after relapse is less successful, for instance
paclitaxel and topotecan offer response rates of 14–20% at the
standard doses (Eisenhauer et al, 1994; ten Bokkel Huinink et al,
1997). There is a clear need for additional treatment options in
these patients who have a poor prognosis. 
Topotecan is a topoisomerase-1 inhibitor developed for the
treatment of a range of solid tumours. In preclinical studies, its
antineoplastic activity was shown to be enhanced when adminis-
tered intermittently or continuously for prolonged periods. A
series of phase I studies established the maximum tolerated doses
(MTDs) of both daily ´ 5 and continuous infusion regimens. A
study in pre-treated patients with solid tumours found that a 21-
day continuous infusion was effective and well tolerated, and 2 of
5 patients with refractory ovarian cancers had partial responses to
treatment (Hochster et al, 1994). The dose-limiting toxicity was
myelosuppression and non-haematological toxicities were
generally mild. In this heavily pre-treated population, the MTD of
topotecan was 0.5 mg/m2/day. 
A phase II programme was carried out in both Europe and North
America to evaluate the activity of the 21-day infusion regimen in
recurrent ovarian cancer because of the results of the phase I study.
A starting daily dose of 0.4 mg/m2/day was chosen due to the
frequent need for dose reduction and/or interruption at the MTD
dose of 0.5 mg/m2/day. The results of the European part of this
programme are reported here. 
PATIENTS AND METHODS 
Patients 
Female patients aged at least 18 years with a histological diagnosis
of metastatic epithelial ovarian cancer were entered into the study
if they had failed first-line therapy with a platinum-based
chemotherapy regimen, i.e. only one prior chemotherapy regimen
was permitted. Patients had to have measurable disease of at least
2 cm in diameter or 1 cm in the case of skin lesions. All patients
required insertion of a permanent venous access device (Hickman
or medi-port) and patients of child-bearing potential were to
practise adequate contraception. Written, informed consent was
obtained from each patient before entry in accordance with the
guidelines set out by local institutional review boards. 
To be eligible for the study patients had to have an ECOG
performance status ≤2, a life expectancy of at least 3 months,
adequate bone marrow function (white blood cell count
³3.5 ´ 109 l–1, granulocytes ³1.5 ´ 109 l–1, platelets ³100 ´ 109 l–1
and haemoglobin ³9g  d l –1) and adequate renal and hepatic func-
tion (serum creatinine ≤130 mmol l–1, bilirubin ≤35 mmol l–1 and
AST and ALT ≤5 ´ the upper limit of normal). At least 4 weeks
had to have elapsed since previous chemotherapy and any
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exposure to radiotherapy were not eligible. Patients with previous
brain or leptomeningeal metastases or concomitant malignancies
at other sites were also excluded, except for those with carcinoma
in situ of the cervix, or basal or squamous cell carcinoma of the
skin. The presence of severe coexisting medical problems
precluded a patient from entry to the study, as did previous
treatment with a camptothecin analogue. 
Treatment 
Patients received a regimen of topotecan (HycamtinTM,
SmithKline Beecham Pharmaceuticals) 0.4 mg/m2/day given as
a continuous intravenous 21-day infusion. Administration of
topotecan was repeated every 28 days and treatment duration
depended on the patient’s response to therapy. The topotecan dose
could be increased or decreased in the range 0.2–0.8 mg/m2/day
and/or delayed depending on toxicity assessed by the Common
Toxicity Criteria. Each subsequent course of treatment began on
schedule provided that there was no evidence of disease progres-
sion, the bone marrow had recovered (neutrophils >1.5 ´ 109 l–1,
platelets >100 ´ 109 l–1, haemoglobin >9.0 g dl–1) and there was
no other clinically significant drug-related toxicity (excluding
alopecia). Otherwise treatment was delayed until recovery. 
A reduction in dose at the next treatment course of 0.1 mg/
m2/day was made in the event of grade 4 neutropenia or grade 3/4
thrombocytopenia during infusion or grade 2 neutropenia or
thrombocytopenia lasting beyond day 28, or any grade 3/4 non-
haematological toxicity. Similar dose reductions were made for
any toxicity which delayed subsequent treatment courses. Dose
escalations, in increments of 0.1 mg/m2/day, were made if there
was no toxicity > grade 2 for 2 consecutive courses and no dosing
delays. No increases in dose were made if the patient had a
complete response to treatment. 
Clinical assessments 
Lesions were assessed by abdominal/pelvic CT, ultrasound or MRI
scan, or chest X-ray and assessments took place either after alter-
nate courses (CT or MRI scan) or at the end of each course (ultra-
sound and chest X-ray). For each patient the imaging technique
was consistent throughout the study. 
Full blood counts were carried out on days 1, 8, 15 and 22 of
each treatment course and blood chemistry on days 1, 8 and 22.
Before each course all laboratory assessments were repeated and
subjective toxicity grades recorded. 
Evaluation of response 
Complete response (CR) was defined as the disappearance of all
measurable and evaluable disease lasting at least 4 weeks. Partial
response (PR) was defined as a decrease of more than 50% in all
measurable lesions for at least 4 weeks with no increase in evalu-
able disease or any other known lesions, or appearance of new
lesions during this period. The time to response was measured
from the first dose of topotecan and duration of response, both CR
and PR, was measured from the time when the response was first
documented to disease progression. Time to progression and
survival were measured from the first administration of topotecan
to progression or death due to any cause, respectively. Responses
were subject to strict independent review by an external board
which included a consultant radiologist. 
Response rate was also evaluated by measurement of serial
CA125 values. Response was defined by a 50% decrease in 2
samples, confirmed by a further sample, or a serial decrease over 3
samples of greater than 75%. The final sample had to be at least 28
days after the previous sample (Rustin et al, 2000). 
RESULTS 
A total of 35 patients entered the study in Europe and demographic
details are summarized in Table 1. All patients had relapsed or
refractory ovarian cancer and had received first-line therapy with
regimens containing carboplatin or cisplatin. Only one patient had
received any other previous treatment (immunotherapy) for her
relapsed disease. The majority of patients had responded to first-
line chemotherapy (17% complete response, 46% partial response)
and the median time to progression from first-line therapy for all
patients was 26.1 weeks (range 3.7–144.7 wks). 3 patients had a
platinum-free interval of >12 months. 
The demographics of this population differed qualitatively from
that of a similar study performed in North America (Hochster et al,
1999, personal communication) with respect to performance
status, tumour bulk, and response to first line therapy. In particular,
18 of 24 (75%) North American patients either had no evidence of
disease prior to first line therapy or a complete response to that
initial chemotherapy. In contrast, only 6 of our 35 (17%) patients
had a complete response to first line therapy (P = 0.001). 
Response and survival 
3 out of the 35 patients (8.6%) had a partial response to treatment
(95% CI 1.8%; 23.1%) which was confirmed on independent
review. 2 further claimed responses were not confirmed on
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Table 1 Patient characteristics 
Number (%) of
patients 
Age (years) Mean (range) 55 (33–74) 
Performance status 0 8 (22.9%) 
1 26 (74.3%) 
2 1 (2.9%) 
Histologic grade 1 2 (5.7%) 
2 9 (25.7%) 
3 11 (31.4%) 
4 4 (11.4%) 
Unknown 9 (25.7%) 
Tumour size (cm) <5 14 (40.0%) 
5–10 15 (42.9%) 
>10 6 (17.1%) 
Best response to first-line 
therapy Complete response 6 (17.1%) 
Partial response 16 (45.7%) 
Stable disease 9 (25.7%) 
Progression 3 (8.6%) 
Unknown 1 (2.9%) 
Time to progression from end of 
first-line therapy
Within 3 months 6 (17%) 
3–6 months 9 (26%) 
6–12 months 17 (48.5%) 
> 12 months 3 (8.5%) independent review. The time to progression from the end of first-
line chemotherapy in these 3 responding patients was 7 weeks, 42
weeks and 46 weeks. The time to response for these 3 patients was
7.0 weeks, 8.1 weeks and 10.9 weeks and the duration of response
was 17.3 weeks, 17.6 weeks and 66.1 weeks. 
25 patients were evaluable for response by CA125 and of these,
2 (8%) were responders. One of these patients responded ac-
cording to both standard and CA125 criteria, the other patient
responded according to CA125 but achieved only stable disease by
standard criteria. This patient had a time to progression from the
end of first-line chemotherapy of 36 weeks. The two remaining
patients who had achieved a response by standard criteria were
CA125-defined nonresponders because their CA125 levels fell
only transiently. 
For all patients in the study, the median time to progression was
16.1 weeks (range 0.9–74.1) and median survival was 43.6 weeks
(range 2.7–95.7, Table 2). 
Toxicity 
The 35 patients in this study received a total of 147 courses of
topotecan (median 4 (range 1–10)). All patients were evaluable for
toxicity. The principal toxicity was myelosuppression (Table 3)
although grade 4 neutropenia occurred in only 8.8% of patients
(2.1% of courses), all during the first course of treatment. The
mean neutrophil nadir was 2.0 ´ 109 l–1 (range 0.2–12.6), observed
approximately 3 weeks after the start of the infusion (mean nadir
day 21.5 range 6.0–47.0). Grade 3/4 infections occurred in 28.6%
of patients and intravenous antibiotics were used in 12.6% of
courses. However fever with infection ³ grade 2 in association
with grade 4 neutropenia occurred in only 2 courses (1.4%). These
2 patients were hospitalized and 1 died from neutropenic sepsis. 
6 additional patients required admission because of infected
indwelling intravenous lines. 
Thrombocytopenia of grade 4 was seen in only 1 patient (2.9%)
during 1 cycle (0.7%). The mean platelet nadir was 183.8 ´ 109 l–1
(range 6–405) and 3 patients (8.6%) received platelet transfusions.
Grade 3 anaemia occurred in 45.7% of patients (11.6% of courses)
and 82.9% of patients received transfusions of red blood cells
(42.2% of courses). 3 patients were hospitalized with anaemia but
no grade 4 anaemia was reported. 
Approximately half the courses (53.1%) were administered at
the starting dose of 0.4 mg/m2/day and 42.9% of courses were
administered at the lower doses of 0.2 or 0.3 mg/m2/day. In almost
all cases the reason for dose reduction was haematological toxicity
which did not appear to be cumulative. Dosing delays occurred in
42.0% of the 112 courses of therapy after course 1, approximately
half of these due to haematological toxicity (22.3% of courses). 
Non-haematological toxicities are shown in Table 4. Apart from
alopecia, the most frequently reported toxicities were nausea
(85.7% of patients), fatigue (48.5% of patients) and vomiting and
abdominal pain (each in 45.7% of patients). Grade 3/4 toxicity was
infrequent except for the incidence of infection (28.6%). 1 patient
was withdrawn from the study due to fatigue possibly related to
topotecan. 
24 of the 35 patients have died, 1 from neutropenic sepsis, the
remaining 23 patients due to progressive disease or other causes
unrelated to study treatment. 
DISCUSSION 
The activity of topotecan in recurrent ovarian cancer has already
been established using a daily ´ 5 regimen at a topotecan dose of
1.5 mg/m2/day for 5 days every 21 days (ten Bokkel Huinink et al,
1997; Bookman et al, 1998). The response rate in a phase II study
with this regimen was 13.7% (Bookman et al, 1998) and 20.5% in
a phase III comparative study of topotecan and paclitaxel (Gordon
et al, 1998). In the latter trial this result was similar to the response
rate of 14.0% obtained with paclitaxel. In this current study,
topotecan 0.4 mg/m2/day given as a continuous 21 day intravenous
infusion every 28 days had a response rate of 8.6%. Although this
is lower than the response rate achieved with a daily ´ 5 regimen,
time to progression does not appear to have been reduced. The
median time to progression of 16.1 weeks is similar to that in the
previous studies of the daily ´ 5 regimen (12.1 and 18.9 weeks)
and median survival was 43.6 weeks compared to 47 and 63 weeks
(Bookman et al, 1998; Gordon et al, 1998). 
Our response rate of 8.6% differs from the 35% observed in
North American patients (Hochster et al, 1999). The patients in
these studies differed with respect to status after first line therapy,
performance status, and tumour bulk. Among these characteristics,
status of CR or NED after first line therapy showed a likely corre-
lation with response in these studies, and may help to explain the
differences in response rates. 
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Table 2 Response to topotecan 
Response All patients (n = 35) 
Complete response (CR) 0 
Partial response (PR) 3 (8.6%) 
Overall response 3 (8.6%) 
Stable disease (SD) 9 (25.7%) 
Time to progression (weeks): median (range) 16.1 (0.9–74.1) 
Survival (weeks): median (range) 43.6 (2.7–95.7) 
Table 3 Haematological toxicity (CTC) with grade per patient 
Toxicity Patients (n = 35) Courses (n = 147)a
Grade 3 Grade 4 Grade 3 Grade 4 
Neutropenia 10 (29.4%) 3 (8.8%) 11 (7.6%) 3 (2.1%) 
Leucopenia 7 (20.0%) 1 (2.9%) 9 (6.2%) 1 (0.7%) 
Thrombocytopenia 5 (14.3%) 1 (2.9%) 6 (4.1%) 1 (0.7%) 
Anaemia 16 (45.7%) 0 (0%) 17 (11.6%) 0 (0%) 
aOne or two courses for each variable with no laboratory data available. 
Table 4 Non-haematological toxicity (CTC), with grade per patient 
Adverse event Grades 1/2 Grades 3/4 
Nausea 28 (80.0%) 2 (5.7%) 
Alopecia 23 (65.7%) NA 
Fatigue 17 (48.6%) 0 
Abdominal pain 14 (40.0%) 2 (5.7%) 
Vomiting 14 (40.0%) 2 (5.7%) 
Constipation 13 (37.2%) 2 (5.7%) 
Infection 5 (14.3%) 10 (28.6%) 
Diarrhoea 14 (40.0%) 0 
NA = not applicable (grade 4 alopecia not defined). Topotecan administered as a 21-day continuous infusion was
found to be well tolerated. The principal toxicity was myelosup-
pression and although infectious complications were relatively
frequent this was mainly due to indwelling intravenous catheter
sepsis. There was no evidence of cumulative toxicity and no G-
CSF was administered either as prophylaxis or treatment. The
degree of neutropenia was considerably reduced compared with
the daily ´ 5 regimen where grade 4 neutropenia was observed in
approximately 35–40% of courses (ten Bokkel Huinink et al,
1997; Bookman et al, 1998) rather than 2% as observed here.
Grade 3/4 anaemia, however, was higher following the continuous
infusion regimen, 46% of courses compared with approximately
10–15% for the standard regimen. Non-haematological toxicity
was generally mild and mainly consisted of grade 1/2 gastroin-
testinal events, alopecia and fatigue. 
In conclusion, a prolonged infusion of topotecan was well toler-
ated with a low incidence of severe neutropenia. Responses were
seen in both North American and European patients but response
rates varied regionally, possibly due to differences in patient
demographics. 
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